Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
Name	Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
Formation	2014
Headquarters	Washington, D.C.
Leader title	Chair
Parent organization	Executive Office of the President

Contents

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria is an advisory body established to provide guidance on antimicrobial resistance policy across federal agencies, interagency programs, and international partnerships. The council advised the President of the United States and coordinated with agencies such as the Department of Health and Human Services, the Department of Defense, the Department of Agriculture, the Centers for Disease Control and Prevention, and the Food and Drug Administration. Its work intersected with initiatives by the World Health Organization, the National Institutes of Health, the European Centre for Disease Prevention and Control, and nongovernmental organizations including the Bill & Melinda Gates Foundation and the Wellcome Trust.

Background and Establishment

The council was created during the administration of Barack Obama following reports by the President's Council of Advisors on Science and Technology and calls from the United Nations and the World Health Assembly to address rising threats identified in publications by Lance J. Price, Thomas Frieden, and the Infectious Diseases Society of America. The establishment followed executive actions similar to prior initiatives like the National Strategy for Counterterrorism and drew on legislative frameworks such as the Public Health Service Act and interactions with Congress including members from the United States Senate and the United States House of Representatives. Early meetings involved stakeholders from the Johns Hopkins Bloomberg School of Public Health, the Harvard T.H. Chan School of Public Health, and industry representatives from companies like Pfizer, GlaxoSmithKline, and Merck & Co..

Membership comprised experts appointed from academia, industry, and federal agencies, drawing individuals affiliated with institutions such as the Centers for Disease Control and Prevention, the National Institutes of Health, the Food and Drug Administration, the Veterans Health Administration, and universities including Yale University, Stanford University, University of Oxford, and University of Cambridge. Chairs and members included clinicians, microbiologists, and public health officials with ties to organizations like the Infectious Diseases Society of America, the American Medical Association, and the American Academy of Pediatrics. The council operated under the Federal Advisory Committee Act and coordinated with international bodies such as the World Health Organization and the Organisation for Economic Co-operation and Development. Administrative support came from the Executive Office of the President and interagency working groups connected to the National Security Council and the Office of Management and Budget.

The council’s mandate included advising on implementation of the National Action Plan for Combating Antibiotic-Resistant Bacteria, recommending priorities for research funded by the National Institutes of Health and the Biomedical Advanced Research and Development Authority, and shaping regulatory approaches at the Food and Drug Administration and the Environmental Protection Agency. Responsibilities extended to strategies for antimicrobial stewardship in settings overseen by the Department of Veterans Affairs, the United States Department of Agriculture, and the Centers for Medicare & Medicaid Services, as well as coordination with international frameworks promoted by the World Health Organization and the United Nations General Assembly. The council issued guidance on surveillance systems linked to the National Healthcare Safety Network and supported partnerships with philanthropic organizations like the Wellcome Trust and the Bill & Melinda Gates Foundation.

The council produced recommendations emphasizing research priorities outlined by the National Institutes of Health, incentives for drug development aligned with policies debated in the United States Congress, and stewardship programs similar to those advocated by the Infectious Diseases Society of America. It endorsed elements from the Review on Antimicrobial Resistance chaired by Jim O'Neill, promoted surveillance harmonization akin to the European Centre for Disease Prevention and Control networks, and supported novel reimbursement models discussed in hearings before the United States Senate Committee on Health, Education, Labor, and Pensions. Recommendations included advancing diagnostics supported by the Biomedical Advanced Research and Development Authority, enhancing infection prevention in facilities overseen by the Centers for Medicare & Medicaid Services, and fostering public–private partnerships with corporations such as Johnson & Johnson and research consortia at institutions like Massachusetts Institute of Technology.

The council influenced updates to the National Action Plan for Combating Antibiotic-Resistant Bacteria and informed policy decisions by the Department of Health and Human Services and the Food and Drug Administration, contributing to funding allocations from the National Institutes of Health and programmatic shifts at the Centers for Disease Control and Prevention. Its recommendations supported expanded surveillance initiatives comparable to programs at the European Centre for Disease Prevention and Control and helped catalyze collaborations among academic centers like Harvard Medical School, Johns Hopkins University, and University of California, San Francisco. Industry responses included commitments from firms such as GlaxoSmithKline and Sanofi to pursue antimicrobial pipelines, while international partners like the World Health Organization and the United Nations incorporated elements into global action frameworks.

Critics from advocacy groups including Public Citizen and commentators in outlets connected to The New York Times and The Lancet argued the council's recommendations favored industry-friendly incentives linked to pharmaceutical companies like Pfizer and Merck & Co. without sufficiently robust mandates for stewardship in systems managed by the Department of Agriculture and the Centers for Medicare & Medicaid Services. Some members raised concerns about conflicts of interest similar to debates involving the Advisory Committee on Immunization Practices and questioned transparency under the Federal Advisory Committee Act. International health scholars associated with London School of Hygiene & Tropical Medicine and Imperial College London called for stronger global coordination than some council outputs provided, urging alignment with reports from the Review on Antimicrobial Resistance and policy proposals debated in the United Kingdom Parliament and the European Commission.